P/E ratio for Zosano Pharma (ZSAN)
P/E ratio at the end of 2021: -1.78
According to Zosano Pharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0385938. At the end of 2021 the company had a P/E ratio of -1.78.
P/E ratio history for Zosano Pharma from 2015 to 2021
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -1.78 | 54.77% |
| 2020 | -1.15 | 88.27% |
| 2019 | -0.6113 | -2.29% |
| 2018 | -0.6257 | 1.19% |
| 2017 | -0.6183 | 72.02% |
| 2016 | -0.3594 | -60.04% |
| 2015 | -0.8996 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Baxter BAX | 7.13 | -18,576.70% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | -0.3121 | 708.57% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.